Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00270556|
Recruitment Status : Completed
First Posted : December 28, 2005
Last Update Posted : April 10, 2008
|Condition or disease||Intervention/treatment||Phase|
|HIV||Drug: tenofovir disoproxil fumarate Drug: Abacavir||Phase 2|
A previous study substituting zidovudine or stavudine to abacavir in patients with severe or moderate lipoatrophy has shown an increase in limb fat (DEXA). This study was conducted over a 24 week period and although improved outcomes were documented by objective measures, DEXA scans, subjective observation did not correspond. Longer-term follow up of these patients is required.
This 48 week study is designed to compare the substitution of the thymidine analogues zidovudine (ZDV) or stavudine (D4T) with either tenofovir DF or abacavir, in patients treated with highly active antiretroviral therapy (HAART), and show improved outcomes on total limb fat mass, improved body shape by dual energy x-ray absorptiometry (DEXA) and computed tomography (CT) scans and improved cholesterol and tryglicerides.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||100 participants|
|Official Title:||Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART.|
|Study Start Date :||January 2003|
|Study Completion Date :||October 2004|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00270556
|Study Director:||Claudio Avila, MD||Gilead Sciences|